Oppenheimer analyst Michael Wiederhorn raised his price target for Addus HomeCare to $80 from $72 following quarterly results. The analyst believes the company continues to perform well operationally, and its rapid M&A pace and balance sheet changes are going to help results take another step forward. He reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.